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ABSTRACT 
AN ASSESSMENT OF HEART RATE VARIABILITY AND BIOMARKERS IN 
NEWLY DIAGNOSED RHEUMATOID ARTHRITIS 
 INTRODUCTION: Rheumatoid arthritis (RA) is the most common chronic systemic 
inflammatory arthritis. In extra articular manifestations of RA cardiovascular system 
involvement is the most important complication which may lead to sudden cardiac death. 
The sudden cardiac death in RA is due to arrhythmia and myocardial infarction. The 
cardiovascular events are due to altered autonomic nervous system function. In RA the 
inflammatory mediators, endocrine abnormalities and autoantibodies lead to autonomic 
imbalance.Aim & Objective :To assess the cardiovascular autonomic functional status in  
the Newly diagnosed rheumatoid arthritis subjects by using Resting  Heart Rate 
Variability analysis as a tool. To evaluate the   individual contribution of inflammatory 
biomarkers such as Rheumatoid factor (RF), C-reactive protein (CRP) and platelet count 
in the pathogenesis of cardiovascular autonomic imbalance. Materials & Methods: The 
age and   gender matched 40 study group diagnosed by using EULAR classification 
criteria 2010and 40 healthy controls were recruited from the Stanley Medical College, 
Hospital.  The short term Heart rate variability analysis in supine position was taken in 
the neurophysiology laboratory, Department of physiology, SMC.  RF, CRP, and platelet 
count were estimated. The overall autonomic tone, parasympathetic drive, sympathetic 
drive and sympatho-vagal ratio were quantified by using various parameters. It included 
standard deviation of all R-R intervals (SDNN),  root-mean square of successive 
differences (RMSSD), and number of R-R intervals differing by >50 ms from adjacent 
intervals (NN50) in the time domain analysis. In frequency domain analysis, low 
frequency (LF) and high frequency (HF), LF/HF and total power were assessed. Data was 
analyzed by using SPSS version 17. For statistical analysis Independent Student t test, 
Chi- Square test and Pearson’s Coefficient were applied. Result:Heart rate and systolic 
BP were higher in patients with RA. SDNN, SDSD, RMSSD, NN50, LF and HF power 
in nu and total power (ms x ms) were significantly lower in patients with RA versus 
healthy controls (P<0.001).LF power in normalized unit was increased in the seropositive 
patients (70.43±15.26) than seronegative patients (52.09±26.5). LF/HF ratio increased in 
seropositive (2.81±2.4) when compared with seronegative patients (2.7±1.7). HF power 
in normalized unit was found decreased in the seropositive subjects (29.19±14.25) than 
seronegative subjects (46.08±24.6).Among the study group 62.3% showed CRP positive 
in their sera. None of the healthy controls showed positivity for both rheumatoid factor 
and C-reactive protein. In the frequency domain measures LF power in normalized unit 
was increased in the CRP positive patients(65.77±20.61) than CRP negative 
patients(63.20±21.8).  HF power in normalized unit was found decreased in the CRP 
positive subjects (33.63±19.16) than CRP   negative subjects (35.53±20.28). There was a 
statistically significant increase in platelet count in the study group (3.14±0.5) when 
compared with   the controls (2.5±0.2). It was statistically significant (P ≤0.000**).  There 
was a significant positive correlation found between platelet count and LF nu ( r =0.313, 
p< 0.01**) LF/HF ratio( r = 0.168,p <0.01**).Thus,We observed reduced HRV in RA 
patients which denotes altered cardiovascular autonomic function. We also observed that 
RF, CRP and platelet count were increased in the study group and   associated with 
increased sympathovagal imbalance. This signifies the importance of these factors in the 
pathogenesis of cardiovascular risk in RA patientsConclusion: The simple, noninvasive 
resting HRV analysis can be included in the routine basic    investigation of RA.  The 
periodic assessment of the biomarkers RF, CRP and   platelet count may help in the early 
diagnosis of cardiovascular complication in RA patients. 
 
Key words: cardiovascular status - rheumatoid arthritis - short term heart rate variability-
RF-CRP-platelet count. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is the most common chronic systemic inflammatory 
arthritis. It is characterized by deforming  symmetrical polyarthritis of varying  
extent  and severity, associated with synovitis of  joint and tendon sheaths, 
articular cartilage loss, erosion of  juxta-articular bone. In extra articular 
manifestations of RA cardiovascular system involvement is the most important 
complication which may lead to sudden cardiac death1. Median life expectancy is 
shortened by an average of 7 years for men and 3 years for women compared to 
control population2 
The sudden cardiac deathin RA is due to arrhythmia and myocardial infarction. 
The cardiovascular events are due to altered autonomic nervous system function. 
Autonomic dysfunction is because of the presence of auto antibodies against 
nerve growth factor, superior cervical ganglion and vagus nerve which leads to 
arrhythmia and myocardial infarction.The ischemia is due to inflammatory 
mediators and immune complex.  In chronic arthritis such as RA, decreased 
responsiveness of hypothalamic-pituitary-adrenal axis causes inadequate 
production of cortisol in relation to inflammation that consequently leads to 
increased sympathetic activity, increased circulating cytokines, decreased local 
synovial sympathetic innervation, altered metabolism of estrogen in the 
synovium and high expression of estrogen receptors in synovial cells; all leading 
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to exacerbation of neuroendocrine abnormalities in RA. Thus in RA the 
inflammatory mediators, endocrine abnormalities and autoantibodies lead to 
autonomic imbalance. 
Among the tests for cardiovascular autonomic function assessment, heart rate 
variability (HRV) is a simple, noninvasive study. It is easy to perform.It is a 
quantification measurement of sinus rhythm variability. It depends on the 
balance between sympathetic and parasympathetic activity of the heart. It detects 
the early impairment of the autonomic balance.3 A high HRV indicates good 
adaptability of the heart. Reduced HRV denotes impaired autonomic function. 
 HRV may reflect changes in body to stress, while other physiological 
parametersare still in "normal" accepted ranges. Some HRV changes maybe a 
first sign ofdistress, reflecting energy more dependent sympathetic system 
involvement. Thedecrease in biological signals variability is a warning sign of a 
homeokinetic self-regulation loss. 
Many studies are available in western countries relating to the cardiovascular 
happenings in RA. However autonomic imbalance evaluating studies in Indian 
population are scanty and the data available are differing.4 Discrepancies might 
be related to the use of different criteria for the diagnosis of autonomic 
dysfunction.  The range of abnormality could due to the inclusion of 
variousnumbers of tests. 
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Our study was planned to assess the autonomic function in patients with RA by 
using resting HRV analysis. To evaluate the association of biomarkers 
rheumatoid factor, C-reactive protein and platelet count with HRV indices. 
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REVIEW OF LITERATURE 
Rheumatoid arthritis 
In 1876 Sir Alfred Garrod an English physician introduced the term rheumatoid 
arthritis.0.5 -1% of adult population is affected by rheumatoid arthritis 
worldwide. In India the prevalence rate is 0.2-0.4% 5. The incidence increases 
between 25 -55 years of age. After that the incidence plateaus until the age of 
75,then it decreases.2  
The female group affected more than the male with a ratio of 2-3:1.This 
preponderance in female is due to the hormone estrogen which stimulates Tumor 
Necrosis Factor α (TNFα) a major cytokine involved in the pathogenesis of   
rheumatoid arthritis.The combined factors of genetic, environmental and 
immunologic factors play an important role inthe etiology6 
Genetic factor: 
First degree relatives of the patients show 2-10 times risk of developing 
rheumatoid arthritis thanthe general population. The alleles are located in the 
Major Histocompatibility Complex class II. The allelic variation in the HLA-
DRB1 gene which is associated with the etiology of   rheumatoid arthritis 
encodes the MHC class II β chain.The shared epitopes (SE) present in HLA DR 
β chain increase the risk of developing the disease by increasing the production 
of anti CCP antibodies. 
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HLA DR β allele with high risk is * 0401 and associated with moderate risk are* 
0101,* 1001 and*0901. High prevalent areas show association with * 1042. 
Genome wide association studies (GWAS) identified non MHC related genes 
that cause RA susceptibility. GWAS based on Single nucleotide 
polymorphisms(SNPs). There are 3 billion base pairs. The encoding protein 
tyrosine phosphatase non-receptor 22 (PTPN22)is an example of non MHC gene. 
Environmental factors: 
Cigarette smoking contributes risk for developing rheumatoid arthritis by 1.5 -
3.5. It is related to rheumatoid factor and anti CCP antibody positive disease. In 
1931 relationship between rheumatoid arthritis and infectious diseases were 
identified. The Epstein Barr virus (EBV), parvo virus b- 19 and mycoplasma 
antibodies are present in serum synovial fluid of rheumatoid arthritis patients. 
Immunological factors: 
RA is an autoimmune disorder mediated by local immune complex formation 
and complement consumption.  Self-reactive antibodies like rheumatoid factor 
and anti CCP antibodies present in sera of patients before the onset of clinical 
symptoms. Sero-positive patients have severe disease activity than sero-negative 
patients. Enhanced T-cell function has been associated with the spontaneous 
production of antibodies. 
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The pathogenesis involved in rheumatoid arthritis are synovial inflammation, 
proliferation and focal bone erosion. The T cell constitutes 30 – 50 % of 
inflammatory infiltrate .The cortical bone layer separate the bone marrow from 
the invading pannus is thin. So the inflammation from synovium penetrates the 
bone marrow easily. 
Pathogenesis: 
The etiological factors genetic, environmental and immunological factors 
produce dysregulation of the immune system. It was proved by the presence of 
RF and anti CCP antibodies in the sera of the patient inthe  sub clinical condition. 
Tobacco smoking inducescitrullination of proteins in the lungs which induce 
self- reactivity.7The infections alter the immune system through Toll like 
receptors (TLRs). The activated T-cell stimulates the inflammatory mediators 
and destroys the cartilage and the bone. CD4+T-cells stimulate B cells which in 
turn produce antibodies. 
Receptor activator of nuclear factor κ B ligand (RANKL) stimulates osteoclast 
and cause bone resorption. Increased expression of RANKL found in rheumatoid 
arthritis. The Wnt system is a family of glycoprotein which promotes cell 
growth.8 The DKK-1 (dickkopf-1) inhibitor of Wnt system thus inhibits bone 
formation. The cytokine TNF α enhances the expression of    DKK-1. 
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Diagnosis: 
In the past 1987 ACR classification was used for diagnosis of RA. Now the 
criteria for rheumatoid arthritis was revised by ACR and European league against 
Rheumatism (EULAR) 9 2010.This criteria gives a score of 0-10. The 
requirement for definite rheumatoid arthritis should fulfill the score of ≥ 6.  
The radiographic findings inform the diagnosis in the later stage. The new 
classification criteria differ in several ways from the older criteria set. The new 
criteria include a positive test for serum anti-CCP antibodies (also termed ACPA, 
anti- citrullinated peptide antibodies) as an item, which carries greater specificity 
for the diagnosis of RA than a positive test for RF. The newer classification 
criteria also do not take into account whether the patient has rheumatoid nodules 
or radiographic joint damage because these findings occur rarely in early RA. It 
is important to emphasize that the new 2010 ACR-EULAR criteria are 
“classification criteria” as opposed to “diagnostic criteria” and serve to 
distinguish patients at the onset of disease who have a high likelihood of 
evolution to chronic disease with persistent synovitis and joint damage  
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TABLE 1 
EULAR CLASSIFICATION CRITERIA 2010 
Classification criteria for rheumatoid arthritis 
joint involvement 
1 large joint (shoulder elbow,hip,knee,ankle) 0 
2-10 large joints 1 
1-3 small joints(MCP,PIP,ThumbIP,MTP, Wrist) 2 
4-10 small joints 3 
>10 joints (at least one small joint) 5 
Serology 
negative RF and negative ACPA 0 
low positive RF low positive anti-CCP antibodies(≤3times 
ULN) 2 
high positive RF high positive anti-CCP antibodies(>3times 
ULN) 3 
Acute phase 
reactants  
normal CRP and normal ESR 0 
abnormal CRP and abnormal ESR 1 
Duration of 
symptoms 
< 6 weeks 0 
> 6 weeks 1 
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Laboratory findings: 
 IgM,IgG and IgA isotypes of RF may present in sera of RA.The 
IgMisotypeis  the frequently measured RF. 
 Anti CCP antibodies also present 
 Slight leukocytosis with normal DC count 
 Thrombocytosis 
 Mild anemia (Hb 10 gm/dl) 
 Elevated ESR and CRP 
 Normal renal, hepatic and metabolic function 
 Normal urine analysis 
 Synovial fluid analysis shows WBC count 5000 to 50000.  
 Antibodies may be found.   
Radiography- Juxta- articular osteopenia is the early finding. 
MRI–hasthe  greatest sensitivity for detecting synovitis. 
USG detects more bone erosion than radiography. 
Self- reactiveIgM antibody presents in the sera of the patients subclinically. Sero- 
positive patient shows high disease activity than sero negative. Rheumatoid 
factor willfix and activate the classic pathway of complement system.  Among 
the IgG, IgM andIgA, IgM antibody is the most common laboratory useful 
antibody.  RF found in synovial fluid and sera of the patient. 
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Serum IgM RF has been found in 75-80% of patients with RA; therefore, a 
negative result does not exclude the presence of the disease. It is also found in 
other connective tissue diseases, such as primary sj gren’s syndrome, systemic 
lupus erythematous, and type II mixed essential cryoglobulinemia, as well as 
chronic infections such as subacute bacterial endocarditis and hepatitis B and C. 
Serum RF may also be detected in 1-5% of the healthy population.   
C-reactive protein is an acute phase reactant.  It is an inflammatory markerfor 
rapid diagnosis of RA.   It is synthesized in liver in response to cytokines, 
particularly IL6. CRP has been suggested to stimulate the complement activation. 
It indicates the disease activity. The test is easy to perform. Low cost.  CRP 
associates with therisk ofdeveloping myocardial infarction. 
High platelet count indicates the increased activity of platelets which leads 
tothrombosis. The intensive stimulation of the bone marrow and increase platelet 
turn over may occur in response to an excess production of inflammatory 
cytokines .The platelets produce clot forming protein.10 
Forerunners in the research field of autonomic function: 
 1898- Langley coined the term Autonomic nervous system 
 1920 –Herring explained Baroreceptor reflex 
 1936- Jordan explained the clinical findings in autonomic neuropathy 
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 1948-Alquist divided the adrenergic receptors into alpha and beta 
receptors 
 1960-SharpeySchafer Taylor identified the symptom of autonomic 
neuropathy, the orthostatic hypotension. 1967 –Bannister   observed the 
same finding. 
 1966- Albert BLevin described the heart rate changes occur during 
valsalva maneuver 
 1970-Ewing and Clark introduced noninvasive cardiovascular tests to 
study autonomic functions 
 1973-Timothy wheeler introduced the study  for vagal function 
 1975-Lipski et al explained the role of NTS  
 1977-Page and Watkins described the orthostatic test 
 1991- Corellic demonstrated the spectral analysis of HRV in rats 
 1992- Ziegler explained spectral analysis of HRV in humans 
 1994- Boo tama et al described parasympathetic and sympathetic 
influence on the heart. 
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Autonomic nervous system: 
The autonomic nervous system is otherwise called involuntary nervous system. It 
is a part of the peripheral nervous system. It controlsthe  subconscious level 
functions like heart rate, digestion, salivation, respiratory rate, pupillary dilation, 
micturition and sexual function. The autonomic nervous system assists the body 
in maintaining a constantinternal environment (homeostasis). Whenever the 
internal stimuli signals aboutderangement of the body's internal environment, its 
autonomic nerves and thecentral nervous system (CNS) commands 
compensatory actions. 
The term autonomic nervous system generally refers to the sympathetic 
andparasympathetic nervous systems, their preganglionic and 
postganglionicneurons and the central components which include the 
hypothalamus and higherlevels of the limbic system. The sympathetic and 
parasympathetic nerves have preganglionic cell bodies, which are located in 
brain stem and spinal cord. 
Axons leave the central nervous system and synapse in specialized ganglia. 
Second order neurons emerging from the ganglia directly innervate the smooth 
muscle and cardiac muscle. 
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The Sympathetic and parasympathetic nervous system are the two types of 
autonomic nervous system.  The sympathetic gives Flight and Fight reactions and 
consists of thethoroco lumbar spinal nerves. The parasympathetic system 
controls slow active reactions and consists of 9, 10, and 11 cranial nerves and 
sacral spinal nerves.The sympathetic and parasympathetic nervous system organs 
work in acoordinated manner-sometimes acting reciprocally and 
sometimessynergistically-to regulate visceral functions. 
Heart is innervated by both sympathetic and parasympathetic fibers. The 
parasympathetic functions in the heart are prominent. The preganglionic 
sympathetic fibers reach the cardiac ganglion. The post ganglionic fibers supply 
the cardiac tissues, muscles of atria and ventricle.  The parasympathetic vagal 
nerves from the vasomotor center medulla supply the Sino- atrial node which contains 
the firing pace maker cells.11The blood vessels are supplied by sympathetic nerve fibers. 
The sympathetic tone controls the blood pressure by the action on arteries and vein. 
The sympathetic fibers release neurotransmitter noradrenaline which binds with 
beta 1 receptor in the cardiac muscle fiber. After the binding of 
neurotransmitter,calcium is released and it causes depolarization and generates 
action potential. 
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Ach neurotransmitter is released from the parasympathetic fibers. They combine 
with M2 muscarinic receptors and cause hyperpolarization by K channel 
opening.Noradrenaline acts on both alpha 1 and 2 receptors and produces 
biphasic response of vasoconstriction and vasodilatation. 
The vasomotor center medulla has three myocardial centers which control 
cardiovascular functions. They are the Nucleustractus solitaries (NTS), the 
cardiovascular excitatory fibers and theinhibitory center.The major sensory 
nucleus of the autonomic nervous system is the nucleus tractus solitaries. It is a 
paired structure present in the lateral areas of medulla. It lies close to the paired 
dorsal motor vagal nucleus ambiguous. In this motor vagal nucleus ambiguous 
the primary sensory information from the baroreceptor integrated. The 
baroreceptors receive signals from the hypothalamus and the cortical areas. 
The excitatory center is situated in the reticular formation of the rostral 
ventrolateral medulla. In this area most of the cells have pace maker properties. 
They provide a phasic excitatory drive to the sympathetic preganglionic neurons 
through reticular spinal pathways. The NTS and the hypothalamus control the 
rate of discharge of the excitatory cells. 
The inhibitory cells are the preganglionic cells situated in the ventral part of the 
nucleus ambiguous and the dorsal motor nucleus of vagus.Both peripheral and 
central signals are connected by brainstem cardiovascular centers. They 
16 
 
formulate appropriate motor response and relay them to theheart motor neuronsof 
the ANS.12When both divisions of the ANS are blocked, the heart rate averages 
about 100beats/min which is called as intrinsic heart rate. However the average 
resting heart rate isabout 70 beats/min in normal adults. The Heart Rate 
estimated at any given timerepresents the balance of the parasympathetic (vagus) 
nerves, which slows HR,and the sympathetic nerves, which accelerate it. The 
heart response time tosympathetic stimulation is relatively slow. The heart 
response time toparasympathetic stimulation is almost instantaneous. 
Parasympathetic toneusually predominates in healthy, resting individuals. The 
heart rate isconventionally measured by noting the number of heart beats 
perminute. 
17 
 
 
 
 
Autonomic innervations of the heart 
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Baroreceptors: 
Baroreceptors arethe stretch receptors monitor the arterial circulation. They are 
called as carotid sinus and aortic arch receptors.The afferent fibers pass through 
the glossopharyngeal and vagus nerves. They terminateat NTS and the 
neurotransmitter is glutamate which is excitatory.The glutamate stimulates 
GABA secreting neurons which inhibit the tonic discharge of vaso constrictor 
nerves. This causesvasodilation which leads to decreasein blood pressure.  
The excitatory fibers from the NTS pass to the vagal motor neurons and cause 
bradycardia.11The baroreceptors sense the arterial pressure changes and pass it to 
the vasomotor and cardiac inhibitory areas thus it produce a reflex feedback 
mechanism to balance out BP and HR. Any drop in systemic arterial pressure 
decreases the baroreceptor inhibitory discharge and this in turn increases the 
blood pressure and vice versa. The baroreceptor system maintains the short term 
regulation of BP. 
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ASSESSMENT OF CARDIOVASCULAR AUTONOMIC SYSTEM 
The test used to assess the cardiovascular autonomic system should have 
acceptable sensitivity, specificity and reproducible. Simple tests are available for 
evaluation of suspected autonomic dysfunction.  They are blood pressure and 
heart rate response to standing, head –up to tilt, carotid sinus massage, sustained 
isometric handgrip,cold presser test,heart rate variation during deep 
breathing,valsalva maneuver and mental arithmetic.  These testsexplain the 
baroreceptor reflexes. However these tests are not commonly performed outside 
of specialist units. 
In view of Ewing et al12 RR interval variations during deep breathing, valsalva 
maneuver and the blood pressure response to standing are the most widely used 
methods for the assessment of cardiovascular autonomic system. In many tests 
these measures have been combined with measurements of catechol amines and 
their metabolites and plasma renin activity to demonstrate the correlation 
between cardiovascular activity and sympathetic nervous system activity. 
To interpret the significance of blood pressure and heart rate variation 
measurement of  muscle sympathetic nerve activity has been used.The other 
pharmacological tests have been used to study the functioning of baroreceptors 
are blockade with atropine,beta blockers or provocations with norepinephrine13 
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So,this field of clinical assessment of cardiovascular autonomic function, in 
rheumatoid arthritis patients, has been of great interest in research people. To 
assess the sympathetic activity in skeletal muscle we can use microneurography. 
It allows a precise, reproducible and quantitative assessment of sympathetic 
activity.Pagane et al 14 in their study demonstrated that the  sympathetic outflow 
to skeletal muscle will not reflect the sympathetic activity of other organs, which 
are also important  for autonomic circulatory control. This is the limitation of the 
microneurographical method. 
For the last two decades, other methods of studying and quantifying 
cardiovascular autonomic function    have become popular. They are heart rate 
variability (HRV), baroreceptor sensitivity and blood pressure variability. 
Heart rate variability:  
HRV is a physiological phenomenon of variation in the time interval between 
heart beats.   The oscillation in the interval between consecutive heart beats as 
well as the oscillation between consecutive instantaneous heart rate.(Task force 
1996).   
Usually, heart rate variability analysis attempts to assess cardiac autonomic 
regulation through quantificationof sinus rhythm variability.  The main inputs 
tosinus nodeare from the sympathetic nervous system and the parasympathetic 
nervous system. Other factors that affect the inputs are the baroreceptor reflex, 
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thermo regulator, hormones, sleep-wake cycle, meals and stress.The sinus 
rhythm time series is derived from the R-R interval sequence of the 
electrocardiogram; by extracting only normal sinus to normal sinus(NN) inter 
beat intervals. 
History:   
 18th century -  Albrecht Von Haller noticed the regularity of heart beat 
 1965 - Hon and Lee noted the clinical relevance of HRV by appreciated 
thefetal distress which was preceded by changes in inter beat intervals 
before the appearance of changes in heart rate. 
 1971 - Sayers and others focused on rhythm imbedded in beat-to-beat 
heart rate 
 1977 - Wolf et al showed association of heart rate to sudden death in post 
MI 
 Late 1980’s -HRV wasconfirmed as a  strong predictor of mortality after 
an acute MI 
 1981 - Axelrod introduced Power Spectral Analysis 
 1996 - Task Force published Standards of Measurement for HRV. 
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Measurement of HRV:  
HRV analysis is done with the derived R-R intervals mainly by three methods. 
• Time domain 
• Frequency domain 
• Non-linear methods       
Time Domain Methods:  
In this method, either the instantaneous heart rate or normal-to-normal (NN) 
intervals, the intervals between successive normal QRS complexes are 
determined.Time domain measures are the simplest to calculate and include the 
meannormal-to-normal (NN) intervals during the entire recording and statistical 
measures of the variance between NN intervals. 
The majority of time domain metrics are statistical methods. It should be 
calculated over a specific and fixed period of time, or epoch, to carry any 
significance. The two epoch "windows" most often used are 24 hours (long term) 
and 5 minutes (short term). Significant results are achieved only by comparing 
SDNN valuesmay be unreliable if they are calculated over epochs that are too 
short. 
SDNN-reflects the variability in the period of recordings. As SDNN gets 
Reduced, HRV gets reduced 
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SELECTED TIME DOMAIN MEASURES 
 
 
 
VARIABLE UNITS DESCRIPTION 
SDNN ms Standard deviation of all NN intervals 
SDANN ms 
Standard deviation of averages of NN 
intervals in all 5 min segments 
RMSSD ms 
The square root of the mean of the sum 
of the squares of differences between 
adjacent NN intervals. 
SDNN index ms 
Mean of the standard deviation of all NN 
intervals for all 5 min segments 
NN50 count ms 
No:of pairs of adjacent NN intervals 
differing by more than 50 ms 
pNN50 % NN50 count divided by the total number 
 
 
SDNN - the standard deviation of NN intervals. Often it is calculated over a 24-
hour period.  It indicates the parasympathetic activity. 
SDANN - the standard deviation of the average NN intervals calculated over 
short periods, usually 5 minutes. 
RMSSD- the square root of the mean squared difference of successive NNs. 
NN50 – the number of pairs of successive NNs that differ by more than 50ms. 
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pNN50 – the proportion of NN50 divided by total number of NNs. 
Frequency Domain Methods: 
Power spectral density (PSD) analysis provides the basic information of how 
power distributes as a function of frequency.For short term recording (about 5 
minutes), frequency-domain methods are generally preferred. In humans the 
following frequency bands have been defined. 
High Frequency band (HF) between 0.15 and 0.4 Hz. 
HFis contributed mainly by vagal activity (parasympathetic nervous system) 
and itsoscillations depend primarily on respiration. 
Low Frequency band (LF) between 0.04 and 0.15 Hz. 
LFis driven by baroreflex mediated as well as centrally generated RR 
oscillations. It is considered as Sympathetic marker by some while others 
determine it to be a combination of sympathetic and parasympathetic activity. 
Very Low Frequency band (VLF) band between 0.0033 and 0.04 Hz. 
Though VLF is attributed to thermal regulation of the body’s internal systems, 
the origin is not very clear. 
Ultra LowFrequency (ULF) band between 0 and 0.0033 Hz. 
25 
 
This ULF is always expressed in 24 hour recordings. It depicts day night 
variations. 
LF/HF ratio: 
The ratio of low-to-high frequency spectral power (LF/HF) has been used as 
an index of sympathetic to parasympathetic balance of heart rate fluctuation. 
This is controversial because of the lack of understanding of the mechanisms 
for the LF component. 
The measurement of VLF, LF and HF power components are measured in 
absolute values of power (milliseconds squared). LF and HF may also be 
measured in normalized units, which represent the relative value of each 
power component in proportion to the total power minus the VLF 
component.Total power is the ultimate measure in PSD which is an indicator 
of autonomic modulation as a whole. 
Non- linear methods: 
1/f scaling of Fourier spectra, fractal scaling exponents in linear methods 
provides more powerful prognostic information than the traditional HR 
variability indexes. 
Poincare plot where two successive R-R intervals are plotted as points. SD1 
and SD2 represent dispersion of points along the line of identity and 
perpendicular to the line of identity respectively.  
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Conversion of ECG signal to HRV
27 
 
Clinical Uses of HRV: 
  HRV is the noninvasive simple test for measuring both cardiovascular 
andnon-cardiovascular autonomic function. 
  To find out the early signs of development of pathological processes or 
the presence of a functional disorder 
  To evaluate the treatment effectiveness and prognosis 
  HRV is used for exercise training in sports physiology 
  To confirm the effect of stress relaxation program (massage, 
exercise, meditation, light therapy and others) 
  HRV analysis is a predictor of risk after MI, arrhythmias. 
  HRV analysis is an early warning sign of diabetic autonomic neuropathy 
HRV and Rheumatoid arthritis: 
Fischer KM 15in his hypothesis  confirmed   the etiologic factors  smoking 
related alterations to the cytokine balance, stress to the immune system, and 
modifications of autoantibodies are strongly associated with development of  
rheumatoid arthritis. Peripheral neuropathy may be due to vasculitis in 
rheumatoid arthritis.  The autonomic neuropathy may develop due to the same 
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pathophysiology and the presence of autoantibodies against nervous tissue or 
amyloidosis .This explanationwas given by Appenzeller 0 et al16 in his study. 
Mayumi Nagata –Sakurai, et al conducted a study in female subjects with 
stable disease activity of RA and found that the patients with RA have a higher 
rate of increase in thickening of the arterial wall. Inflammation and calcium 
mobilization are factors closely associated withthe accelerated arterial wall 
changes17 
Geneon et al.18  found there was a decreased autonomic nervous system function 
in patients of rheumatoid arthritis with duration of the illness less than 1 year. 
This decrease was associated with severity of pain and also related to the 
pathophysiology of RA.The auto antibodies against nerve growth factor, cervical 
ganglia and vagus nerve were present in rheumatoid arthritis patients who had 
cardiovascular ANS dysfunction19. Maule et al  assessed the antibodies by using 
rabbit tissue as substrate.  They performed four standard cardiovascular function 
tests. Confirmed the autonomic dysfunction in connective tissue disorders and 
suggested autoantibodies against ANS structures 20. 
Stevens RJ et al.21studied the similarity of inflammatory processes occurring in 
RA and cardiovascular disease suggesting RA itself is the risk factor for 
CVD.Levy at al.  Conducted a meta-analysis study to evaluate more accurately  
the incidence of cardiovascular events in RA. 17 publications and abstracts were 
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identified and 15 were selected for the study. He concluded RA patients had an 
excess risk of fatal myocardial infarction compared to general population. The 
prevention of cardiovascular complication should be taken into account by the 
rheumatologist.22 
In the study done by Prior P et aldiscussed that the most common complication 
of RA was cardiovascular dysfunction and it leads to high mortality. In his study 
489 patients with definite or classical RA was followed for a mean of 11.2 years. 
Cohort analysis showed a 3 fold increase in mortality. 23 
Turesson et al 24 suggested” Development of rheumatoid arthritis is thought to be 
an inflammatory process from early arthritis through rheumatoid arthritis and 
possibly to severe extra-articular rheumatoid arthritis” He observed 
autoantibodies associated with the development of extra articular manifestations. 
In 1994 Huikuri HV et al 25showed the relationship between Heart rate variability 
and progression of atherosclerosis. No correlation was found between   HRV 
parameters and age factor   of rheumatoid patients in the  study done by 
Anichkov et al26 
Lombardi F et al27in their study suggested reduced heart rate variability 
associated with increase in sympathetic and decreased vagal tone of sinus node. 
Laden et al.28found  increased resting heart rate in patients with rheumatoid 
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arthritis.  The increased resting heart rate in rheumatoid arthritis was confirmed 
by Pihaetal.29 Theyfound there was no parasympathetic cardiovascular reflex test 
abnormalities.  
The elevated heart rate in RA may be due to decreased parasympathetic tone. 
This decrease is due to increased central sympathetic activity which inhibit the 
parasympathetic vasomotor center was suggested by Loutherenoo W et al 30 
Saraswathi et al in their study confirmed the presence of   parasympathetic 
nervous system dysfunction in rheumatoid arthritis patients. Also suggested 
seropositive or seronegative will not affect the severity of the disease31 
 Spectral analysis of heart rate variability (HRV) in RA patients have revealed a 
decrease in high frequency (HF) power which  indicating  vagal inhibition in 
addition to an increase in low frequency (LF) power indicating sympathetic 
activation. It was observed by Kamal 32 in his study. 
Yadav and colleagues33have studied in detail about the HRV indices in RA 
patients and correlated with immunological and biochemical parameters. They 
observed a decrease in total power (TP) of HRV in RA patients of Indian 
population. This indicates poor cardiovascular health of these patients 
From the studies carried out among western population, it has been observed that 
sympathetic nervous system activity is significantly elevated in RA patients. 
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Spectral analysis of heart rate variability (HRV) in RA patients have revealed a 
decrease in high frequency (HF) power representing vagal inhibition in addition 
to an increase in low frequency (LF) power indicating sympathetic activation. It 
was suggested that the increased incidence of sudden cardiac death in these 
patients could have been due to the decreased vagal drive to the heart. The 
magnitude of cardiovascular autonomic imbalance was linked to cardiovascular 
risks in patients suffering from RA. Reduction in HRV, prolongation in QTc 
interval and higher sympathetic and decreased vagal drive were proposed as 
significant risk predictors for onset of sudden cardiac death in RA. The 
cardiovascular autonomic dysfunction was suggested to stem from the 
underlyingproinflammatory cytokines in RA. 
Del Rincon ID et al34 in their study did not find any traditional risk factors 
associated with cardiovascular events in rheumatoid arthritis.Both seropositive 
and seronegative patients showed autonomic neuropathic changes in the study 
done by Edmonds et al 35. 
80% of all patients with rheumatoid arthritis will be seropositive for rheumatoid 
factor. But only 40% are showed seropositive at clinical onset of the disease. 
This is the conclusion attained by Kuriyaet al36in their study. 
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In the study by Richardson C37 depicted the importance of CRP as a serological 
marker for evaluating acute disease activity.  Wolfe F   in his study   reported 
aboutthe association of CRP with factors such as age, smoking, coronary artery 
disease, increased cholesterol and glucose levels. He concluded positive 
correlation between them.38 
Rantapaa-Dahlqvist S et al 39supportedthe earlier studies finding that elevated 
levels ofrheumatoid factor can be present many years before the clinical 
manifestation of arthritis 
S Van Doormen  et  al40 depicted  oxidative stress,  hyperinsulinemia, oxidized 
low density lipoprotein (oxLDL), C-reactive protein (CRP), tumor necrosis 
factor alpha (TNFα), interleukins -1, -6, -18, RANK ligand, matrix  
metalloproteinase, and adipocytokines  as  platelet agonists. They all increased 
in RA patients.  
Farr M et  al  in their study found out an  increased number of platelets and 
platelet-derived proteins  (growth factors) within the  synovium  and synovial 
fluid.41 Andresen GK  and his colleagues  suggested  high platelet counts in 
synovial fluid and rheumatoid factor (RF) associated with inflammatory 
arthritis, but not osteoarthritis 42 
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Schmitt-Soddy M et al their study in the murine confirmed activated platelets, 
alone or together with other inflammatory cells and mediators   play a 
significant role in thrombus formation, synovial microcirculation, and 
destruction of cartilage.43 
Markers of inflammation such as CRP, ESR and WBC and platelet count have 
been significantly and positively correlated with cardiovascular disease. This 
result was obtained by Huang ZS et al in their study.44 
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AIM AND OBJECTIVE OF STUDY 
 The aim of the study was 
1. To assess the cardiovascular autonomic nervous system function in 
the newly diagnosed   rheumatoid arthritis subjects. 
2. To evaluate rheumatoid factor, C-reactive protein and platelet 
count in RA subjects. 
 The objective of the study was  
1. To assess the cardiovascular autonomic system by using the resting 
heart rate variability analysis. 
2. To assess the individual contribution of inflammatory markers 
rheumatoid factor, C-reactive protein and platelet count to the 
genesis of sympathovagal imbalance.  
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MATERIALS AND METHODS 
Study Design: Case control study     
The study was conducted at Neurophysiology laboratory, Department of 
Physiology, Govt. Stanley Medical College, Chennai.  The Institutional 
Ethical Committee approval was obtained. 
Instrument: 
The Heart Rate Variability recording and analysis was done by using RMS 
polyrite D 2.2 hardware which was connected with a window based PC. Using 
2.5.2 software the instantaneous heart rate at RR intervals were continuously 
plotted. This software is provided with data base, filter settings and calculation 
stools. It stores records. 
Selection of subjects: 
Cases:  
40 newly diagnosed rheumatoid arthritis patients from the Rheumatology 
outpatient department, Govt. Stanley Medical College, Hospital, and Chennai 
were recruited. 
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Controls: 
40 apparently healthy, age and sex matched controls were selected from the 
hospital and college staffs and also healthy persons accompanying the patients. 
Inclusion Criteria: 
 Age group of 20 to 60 years including both gender. 
 Diagnosed rheumatoid arthritis by using the EULAR 
classificationcriteria-2010.  
 Patients who were newlydiagnosed and  not yet started treatment 
Exclusion Criteria: 
 Smoker  and alcoholic. 
 Subjects with chronic diseases such as diabetes mellitus, renal 
failure and other diseases       
 Subjects who are taking drugs  which are known to affect the 
autonomic nervous system.                      
 Subjects with hypertension, Cardiovascular disorders, Endocrine 
disorders,  
 Bronchial asthma and Neurological diseases  
 Pregnant subjects. 
 Subjects with hemoglobin value less than 10 gm. /dl. 
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Methodology: 
 The study was done between 10 A.M. and 1 P.M in the neurophysiology 
laboratory. 
 The lab was kept calm, the temperature was maintained between 25 to 280 
C with minimal lighting. 
 A 2hour fasting was ensured prior to recording including liquids. 
  Subjects were asked to empty the bladder.      
 A complete instruction about the study was given to the subject and 
their doubts cleared. 
 After that the informed and written consent were obtained from the 
subjects. A brief preliminary general and clinical examination of the 
subjects was made. 
The subjects were made to relax and comfortable. 2ml of blood for RF and 
CRP tests, 1.8ml of blood in EDTA coated test tube for platelet count were 
collected. Height in centimeters and weight in kilogram were taken. 
In all subjects in supine position,the blood pressure, heart rate, respiratory rate 
were recorded after 10-15 minutes rest of the subjects. 
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The electrodes were fixed after cleaning with spirit in the following places- 
ELECTRODE POSITION 
Exploring Electrode Right  forearm 
Exploring Electrode  Left forearm 
Reference Electrode Right leg 
 
 The continuous lead II Electrocardiography was acquired for 10 minutes. 
During the recording the subjects were awake with eyes closed. The ECG 
findings with normal sinus rhythm of 5 minutes were taken for analysis. 
Careful analysis was done to exclude intervals between ectopic beats and 
artifacts. 
The recording and analysis were done as described by the Task Force of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. 
Heart rate variability was assessed by time domain and frequency domain 
analysis.  The mean heart rate, standard deviation of all R-R intervals (SDNN), 
root-mean square of successive differences (RMSSD), and number of R-R 
intervals differing by >50 m sec from adjacent intervals (NN50) were measured in 
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the time domain analysis. Spectral measures were obtained by the fast-Fourier 
transform method. The power in the heart rate spectrum between 0.003 and 0.40 
Hz was defined as total power (ms×ms), and was specified as low frequency [LF, 
(0.04-0.15 Hz), predominantly marker of sympathetic activity] and high 
frequency [HF, (0.16-0.4 Hz), marker of parasympathetic activity]. Also the ratio 
of low-to-high frequency power (LF/HF), reflecting the sympathovagal balance 
was measured, where a high value of this ratio indicated sympathetic dominance 
of cardiac autonomic drive.  
Measurement of Biomarkers:  
Evaluation of serum rheumatoid factor and C - reactive protein were done at 
immunology lab in Stanley Medical College. The estimation of platelet count was 
done at clinical pathology lab in  Stanley Medical College. 
Serum rheumatoid factor and C - reactive protein were estimated by Latex 
agglutination test. Platelet count estimation was done by using automated cell 
counter. 
CRP usually appears in the sera of patients in the acute stages of a number of 
inflammatory conditions such as most bacterial and some viral infections; acute 
rheumatoid fever with or without carditis; rheumatoid arthritis and most other 
collagen diseases; and other conditions characterized by inflammation. CRP is 
considered to be a sensitive indicator of inflammation. Changes in the serum 
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level of CRP with time from the same patient can be used as an index of 
recovery. The use of the CRP test to measure the effectiveness of therapy is of 
great clinical significance.  
Since the discovery that rabbits form precipitating antibodies against CRP, 
various immunoprecipitation techniques have been applied for its detection. The 
PATHOZYME CRP TEST is based on the latex-agglutination method. The 
principle of this test is based on the immunological reaction between CRP as an 
antigen and the corresponding antibody coated on the surface of biologically inert 
latex. 
Procedure: 
Contents of RF& CRP latex agglutination kit 
CRP (or) Rheumatoid Factor   latex 50 tests, 
 Concentrated glycine buffer, 
 Positive control,  
 Negative control, 
 50 pipette stirrers and 
 Agglutination slide. 
By using   Qualitative agglutination test method serum CRPand Rheumatoid 
Factor estimation were done.  Serum from the fresh blood sample was 
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obtained by centrifugation. 50µl of sample was placed and one drop of 
positive and negative controlswas placed into separate circles on the slide test.  
The latex reagent was swirled gently before using and added one drop (50µl) 
to the samples to be added. Mixed the drops with a stirrer and spreaded them 
over the entire surface of the circle. Weused different stirrers for each sample. 
After that the slide was placed on a mechanical rotator at 80-100 rpm for 2 
minutes and examined macroscopically forthe presence or absence of the 
agglutination immediately. 
The presence of agglutination indicates a CRP concentration equal or greater 
than 6 mg/l, in case of Rheumatoid factor greater than 14 IU/L. 
Alpha granules and dense bodies of platelets, activated by systemic rheumatoid 
Inflammation, may release their own inflammatory and immune mediators, 
facilitatinginitiation and propagation of synovitis.  Inhibition of platelets with 
subsequent decrease ofplatelet-derived inflammatory markers may have 
beneficial effect on the course of arthritis. 
 The platelet count was obtained by automated cell counter by the principle of 
comparing the low angle and high angle light scatter created by each particle 
from the blood collected in the EDTA coated tube. This study did not involve 
administration of any drugs at any stage. 
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Statistical analysis: 
The acquired data were analyzed by using SPSS version 17.  Descriptive 
statistics   mean, standard deviation were used to explain the characteristics of 
the data.  
Student Independent t test: 
As the cases and the controls were independent samples we applied 
independent student t test to find out the significant difference. Here P<0.05 
taken as significant* and P<0.01 was taken as highly significant** 
Pearson correlation: 
For assessing correlation between two randomvariables Pearson correlation was 
applied. In our test to find out the linear relationship between biomarkers for 
rheumatoid arthritis  and Heart rate variability parameters Pearson’s correlation 
analysis was utilized 
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RESULTS 
TABLE 2  
  Baseline characteristics of the studyand the control group 
 
 Group N Mean 
Std 
Deviation 
Student  
independent 
t test 
Age in 
years 
Cases 40 41.57 7.82 t =0.298 
p =0.767 Control 40 41.25 7.88 
BMI 
Cases 40 24.48 3.19 
t =0.831 
p = 0.934 Control 40 24.43 2.79 
 
Observation 
The age and BMI in the study and the control group do not show 
any statistically significant difference. Hence both the study and 
the control groups are comparable. 
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TABLE 3 
Comparison of mean HR, SBP and DBP in the study and the 
control group 
 Group N Mean Std deviation p value 
Mean 
HR(bpm)   
Cases 40 79.55 7.78 
p =0.000** 
Control 40 70.83 7.52 
SBP 
(mmHg) 
Cases 40 118.3 7.102 
p =0.001** 
Control 40 108.3 10.104 
DBP 
(mmHg) 
Cases 40 71.6 6.03 
p =0.931 
Control 40 71.7 4.08 
 
** Highly significant 
Observation:  
The mean HR was significantly increased in the study group than 
control. The Systolic Blood Pressure was significantly increased 
in the study group than control.The Diastolic blood pressure did 
not show any statistically significant variation.  
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FIGURE 1 
Comparison of heart rate between the study and the control 
group 
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FIGURE 2 
Comparison of SBP and DBP between the study and the 
control group 
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TABLE 4 
Comparison oftime domain measures in supine 
positionbetween the study and the control group 
Parameter study control Independent  t value P value 
Mean 
HR(bpm) 
Mean SD Mean SD 
79.55 7.78 70.83 7.52 5.09 0.000** 
Mean RR 
(ms) 
731.08 167.8 837.96 89.35 3.55 0.001** 
SDNN  (ms) 24.97 8.9 51.64 25.35 6.27 0.000
** 
RMSSD 
(ms) 
22.92 12.77 55.73 33.44 5.79 0.000** 
NN 50 246.32 252.4 106.85 76.41 6.04 0.000
** 
 
** Highly significant 
 
Observation: 
There was a significant reduction of SDNN and RMSSD in the 
study group compared to controls. There was a significant 
increase in mean HR in the study group than control. 
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FIGURE 3 
Comparison of time domain measures in supine position 
between the study and the control group 
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TABLE 5 
Comparison of frequency domain measures between the study 
and the control group 
 
Parameter study control 
Independent  
t value 
P value 
  Mean SD Mean SD 
LF n.u. 64.74 20.87 52.02 14.63 4.98 0.000** 
HF n.u. 34.39 19.38 45.94 14.68 5.91 0.000** 
LF/HF 2.79 2.33 1.04 0.66 5.83 0.000** 
 
** Highly significant 
Observation: 
The LF power in n.u. and LF/HF ratio were increased in the study 
group than control. The HF power in n.u was decreased inthe 
study group than control. 
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FIGURE 4 
Comparison of frequency domain measures betweenthe study 
and the control group 
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TABLE 6 
Comparison of time domain measures in sero positive and 
sero negative subjects in study the group 
 
 
Sero-positive Sero-negative 
t test P value 
Mean SD Mean SD 
HR(bpm) 79.97 7.8 77.88 7.7 0.676 0.5 
RR (ms) 755.34 83.16 634 335.8 1.88 0.06 
SDNN (ms) 24.6 8.89 26.44 9.55 0.516 0.6 
RMSSD (ms) 20.76 11.26 31.6 15.47 2.25 0.03* 
 
*  significant 
 
Observation: 
The RR interval, SDNN and RMSSD were decreased in the sero 
positive subjects than sero negative. 
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FIGURE 5 
Comparison of heart rate in sero-positive and sero-negative 
subjects in the study group 
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FIGURE 6 
Comparison of SDNN AND RMSSD in sero positive and sero 
negative subjects in the study group 
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TABLE 7 
Comparison of frequency domain measures in sero positive 
and sero negative subjects in the study group 
 
 
Sero-positive Sero-negative 
T test P value 
Mean SD Mean SD 
LFn.u. 70.43 15.26 52.09 26.5 1.59 0.111 
HFn.u. 29.12 14.25 46.08 24.6 1.472 <0.01** 
LF/HF 2.81 2.4 2.7 1.7 1.46 0.944 
 
** Highly significant 
Observation: 
The LF power in n.u.and LF/HF were increased in sero positive 
when compared withsero negative subjects. The HF power in n.u. 
was decreased in the sero positive when compared with sero 
negative subjects. 
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FIGURE 7 
 
Comparison of frequency domain measures in sero positive 
and sero negative subjects in the study group 
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FIGURE 8 
Comparison of LF/HF ratio in sero positive and sero negative 
subjects in the study group 
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TABLE 8 
Comparison of time domain measures in CRP positive and 
CRP negative subjects in the study group 
 
 
CRP-positive CRP-negative 
P value 
Mean SD Mean SD 
HR(bpm) 79.36 6.78 79.86 9.47 0.857 
RR (ms) 735.28 154.91 724.06 192.92 0.849 
SDNN (ms) 24.62 8.82 25.56 9.39 0.754 
RMSSD (ms) 22.28 13.05 24.01 12.68 0.68 
 
Observation: 
No significant difference was found in time domain measures 
between CRP positive and CRP negative subjects 
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FIGURE 9 
Comparison of time domain measures in CRP positive and 
CRP negative subjects in the study group 
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TABLE 9 
Comparison of frequency domain measures in CRP positive 
and CRP  negative  subjects in the study group 
 
 
CRP-positive CRP-negative 
P value 
Mean SD Mean SD 
LF nu 65.77 20.61 63.20 21.8 0.628 
HF nu 33.63 19.16 35.53 20.28 0.37 
LF/HF 2.76 2.4 2.76 2.28 0.93 
 
 
Observation 
There was increased LF power in normalized units and LF/HF 
ratio in the CRP positive subjects. There was decreased HF power 
in normalized unit found inthe CRP positive subjects. However 
those were not statistically significant. 
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FIGURE 10 
Comparison of frequency domain measures   in CRP positive 
and CRP  negative  subjects in thestudy group 
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FIGURE 11 
Comparison of platelet count between the study and the 
control group 
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TABLE 10 
Correlation   between mean RR and platelet count in the study group 
 
 
Correlation coefficient 
and p value 
Interpretation 
Correlation  between  
mean RR and platelet 
count 
r = 0.093  
P = 0.341 
Positive correlation                
Not  significant 
 
TABLE 11 
Correlation   between   SDNN and platelet count in the study group 
 
Correlation coefficient 
and p value 
Interpretation 
Correlation  between  
SDNN and platelet count 
r =  -0.138   
P = 0.000** 
Negative 
correlation                
Highly significant 
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TABLE 12 
Correlation   between  RMSSD and platelet count in the study group 
 
Correlation coefficient 
and p value 
Interpretation 
Correlation  between  
RMSSD and platelet 
count 
r =  -0.218   
P = 0.000** 
Negative 
correlation                
Highly significant 
 
TABLE 13 
Correlation   between LF nu and platelet count in the study group 
 
Correlation coefficient 
and p value 
Interpretation 
Correlation  between  LF 
nu and platelet count 
r  =   0.313                              
P = 0.000** 
positive correlation                
Highly significant 
 
  
 
 
 
64 
 
 
TABLE 14 
Correlation   between HF nu and platelet count in the study group 
 
Correlation coefficient 
and p value 
Interpretation 
Correlation  between  HF 
nu and platelet count 
r  = - 0.194                               
P = 0.000** 
Negative  
correlation                
Highly  significant 
 
TABLE 15  
Correlation   between LF/ HF Ratio and platelet count in the study 
group 
 
Correlation coefficient 
and p value 
Interpretation 
Correlation  between  
LF/HF ratio  and platelet 
count 
r  =  0.168                               
P = 0.000** 
Positive correlation                
Highly  significant 
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RESULTS 
Statistical Package for Social Sciences (SPSS) 17 version was used for statistical 
analysis. An Independent Student t test, Chi- square test andPearson’s coefficient 
were applied for analysis. 
Table- 2 shows no significant difference in age and BMI between the study and 
the control group. 
Table-3 shows significant increase in HR in the study group than the control. The 
Systolic Blood Pressure was significantly increased in the study group than the 
control.The Diastolic blood pressure did not show any statistically significant 
variation. 
Table-4 There was a significant reduction of SDNN and RMSSD in the study 
group compared to controls. There was a significant increase in mean HR in the 
study group than control. 
Table-5 shows the LF power in n.u. and LF/HF ratio were increased in the study 
group than the control. The HF power in n.u was decreased in the study group 
than the control. 
Table-6 shows the R-R interval, SDNN and RMSSD were decreased in the sero 
positive subjects than thesero negative. 
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Table-7 showsthe LF power in n.u. and LF/HF were increased in sero positive 
when compared with sero negative subjects. The HF power in n.u. was decreased 
in the sero positive when compared with sero negative subjects. 
Table-8 shows nosignificant difference in time domain measures between CRP 
positive and CRP negative subjects. 
Table-9 shows increased LF power in normalized units and LF/HF ratio in the 
CRP positive subjects. There was decreased HF power in normalized unit found 
in the CRP positive subjects. However those were not statistically significant. 
Table- 10 shows weekly positivecorrelation   between mean RR and platelet 
count in the study group. 
Table-11 shows significant negative correlation   between   SDNN and platelet 
count in the study group. 
Table-12 showssignificant negative correlation   between   RMSSD and platelet 
count in the study group. 
Table-13 shows significant positive correlation   between LF nu and platelet 
count in the study group. 
Table-14 shows significant negative correlation   between   HF nu and platelet 
count in the study group. 
Table-15 shows significant positive correlation   between LF/HF ratio and 
platelet count in the study group. 
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DISCUSSION 
The most common extra articular complication of RA is cardiovascular 
involvement. The pathogenesis is mediated by the involvement of inflammatory 
mediators and auto antibodies. An early diagnosis and management of the 
cardiovascular complication in RA improves prognosis and the quality of life. 
HRV is a noninvasive technique to assess the autonomic nervous system function 
in both normal and diseased subjects 12 
The resting short term heart rate variability analysis in supine position showed 
the following results. 
Baseline parameters 
The mean age of the study group was 41.01±7.94. The mean age of control was 
41.58±7.8. The mean BMI of study group was 24.48±3.19. The mean BMI of 
control was 24.43±2.79. Both parameters were statistically comparable. Thus the 
influence of age, BMI and gender on the cardiovascular autonomic system was 
alleviated by selecting age, BMI and gender matched subjects for the study.   
 The resting heart rate in the study group was 79.55±7.7. The control group was 
70.83±7.5. The resting heart rate was found tobe significantly increased (p value 
<0.001**)   in the study group than the control. The mean systolic blood pressure 
of study group was 118.3±7.06.The mean SBP of control group was 
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108.35±10.1. The SBP was significantly increased (p value 0.001**) in the study 
group than control.  These findings indicate the presence of sympathetic over 
activity in the RA patients. These findings were in accordance with the findings 
of Laden et al45Piha et al29 studies. The reason for increased heart rate can be due 
to the parasympathetic efferent vagal damage which was suggested by Ewing et 
al12 in his study. HRV is a valuable, noninvasive tool to assess the autonomic 
neural function. 
Any alteration in resting HRV is associated with increased risk of adverse 
cardiac events. Analysis of the resting heart rate variability of a 5 minutes 
recording done using the HRV analysis software version2.2 among both the 
study and the control  groups showed the following results. 
Frequency domain parameters 
In HRV, the frequency domain parameter LF power in normalized unit was 
increased in the study group(64.74±20.87) than the control(52.02±14.64).This 
was statistically significant(p<0.01**) This indicates the sympathetic over activity 
in the RA patients.  The HF power in normalized unit was significantly lower in 
the study group (34.39±19.38) than the healthy controls (45.94±14.68). This was 
statistically significant (p<0.01**). This indicates the parasympathetic withdrawal 
in RA patients. The total power also reduced in the study group when compared 
to control but it was not statistically significant. This denotes the depressive state 
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of the cardiovascular autonomic nervous system in the RA patients. LF/HF ratio 
was increased in the study group (2.79±2.33) than the controls (1.04±0.66) and it 
was statistically significant (p<0.01**). This indicates the sympathovagal 
imbalance in the RA patients. The overall frequency domain parameters in our 
study indicate the state of depressed vagal tone on the heart and the altered 
sympathovagal balance in RA patients.  
Our study findings were in accordance with the findings of Everngul et al 47 
study. He observed a significant decrease in HF and increase in LF and LF/HF 
ratio, signifying predominance of the sympathetic activity of the heart. 
Conversely in the study done by Yadavet al.33 in Indian population, he observed 
a decrease in both LFms2 and HFms2   and concluded reduced HRV in RA 
patient. 
Sandhuetal46 has suggested that increased heart rate may be due to increased 
sympatheticactivity and decreased parasympathetic vagal tone. This decreased 
parasympathetic tone may lead to increased heart rate.  
In our study 80 % of the study group was positive for RF and   20% were sero 
negative. This may be due to the selection of the study group from 
Rheumatology outpatient department.  Kuriya B (36),Boultry N,48  and Machold 
KP49 concluded  in their studies 80% of all patients with rheumatoid arthritis will 
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eventually be  seropositive for rheumatoid factor. But only 40% are positive at 
clinical onset of the disease. 
Sune F Nielsen et al did a prospective cohort study, for 20 years since 1981 to 
2010 august.9712 individuals from the general population were included. In that 
study the authors came to a conclusion that individuals in the general population 
with elevated rheumatoid factor have up to 26-fold greater long term risk of 
rheumatoid arthritis. 
 In the frequency domain measures LF power in normalized unit was increased in 
the seropositive patients (70.43±15.26) than seronegative patients (52.09±26.5). 
LF/HF ratio increased in seropositive (2.81±2.4) when compared with 
seronegative patients (2.7±1.7). These indicate the sympathetic over activity in 
the seropositive patients.  HF power in normalized unit was found decreased in 
the seropositive subjects (29.19±14.25) than seronegative subjects (46.08±24.6). 
It was statistically significant (p<0.01**).It indicates the parasympathetic 
withdrawal status in the seropositive patients. 
Among the study group 62.3% showed CRP positive in their sera. None of the 
healthy controls showed positivity for both rheumatoid factor and C-reactive 
protein. In the frequency domain measures LF power in normalized unit was 
increased in the CRP positive patients (65.77±20.61) than CRP negative patients 
(63.20±21.8).  These indicate the sympathetic predominance in the CRP positive 
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patients. HF power in normalized unit was found decreased in the CRP positive 
subjects (33.63±19.16) than CRP   negative subjects (35.53±20.28). It indicates 
the parasympathetic withdrawal status in the CRP positive patients. It was not 
statistically significant (p =0.765).This may be due to small sample size. 
 There was a statistically significant increase in platelet count in the study group 
(3.14±0.5) when compared with   the controls (2.5±0.2). It was statistically 
significant (P ≤0.000**).   A significant positive correlation was found between 
platelet count and LF nu ( r =0.313, p< 0.01**) LF/HF ratio( r = 0.168,p <0.01**). 
These results indicate an association of increased platelet count with impaired 
sympathovagal balance.  
Time domain parameters 
In our study the resting heart rate was significantly increased in the study group 
(79.55±7.78) than control group (70.83±7.52).It was statistically significant 
(p<0.01**). It indicates the increased sympathetic activity in the RA patients. The 
SDNN in the study group (24.97±8.9) was found to be decreased than control 
(51.64±25.35). It was statistically significant (p<0.01**). The RMSSD   was 
found reduced in the rheumatoid arthritis patients (22.92±12.77) than the healthy 
controls (55.73±33.44).It was statistically significant (p<0.01**). It indicates the   
parasympathetic withdrawal in RA patients. Similar findings were observed in   
Evrengal H et al46, Maule S et al 20Louthrenoo W30 and Yadav33 studies. 
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 In case of RF the RR interval was reduced in the seropositive subjects 
(755.35±83.16)and seronegative subjects (634±335).The SDNN was reduced in 
the seropositive subjects (24.6±8.89) than theseronegative subjects (26.44±9.55).  
The RMSSD was decreased in the seropositive patients (20.76±11.26) when 
compared with sero negative (31.6±15.47).  It was statistically significant 
(p<0.03*). These results indicate the parasympathetic withdrawal status in the 
CRP positive patients. The findings were in accordance with the findings of 
previous studies done by Sandhu V et al47, and Castro EM et al50. 
 The SDNN was reduced in the CRP positive subjects (24.6±8.89) than CRP 
negative subjects (25.54±9.55).  The RMSSD was decreased in the CRP positive 
patients (22.26±11.26) when compared with CRP negative (24.01±15.47).  The 
RR interval was variable in the CRP positive subjects (735.35±83.16) when 
compared with the CRP negative subjects . 
These results reveal that C-reactive protein is associated with cardiovascular 
autonomic imbalance in the RA patients. CRP is an important inflammatory 
marker in RA patients and might be involved in the pathogenesis of 
cardiovascular complication.  Similar result was observed in the study of 
R.T.Keenanet al.51 
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 A significant negative correlation was found between platelet count and SDNN 
(r = - 0.138, p <0.01**) and RMSSD (r = - 0.21, p< 0.01**) of time domain 
measures. Platelets are involved in the inflammation, atherosclerosis and 
thrombosis in RA patients. Cardiovascular and RA-associated factors can 
increase circulating platelet count and alter the structure and function of platelets, 
by reactive megakaryocytopoiesis. Hyperactive platelets target synovial 
membranes with subsequent local rheumatoid inflammation. Hyperactive 
platelets interact with other cells, and target the vascular wall and lead to 
cardiovascular risk in RA subjects. 
 Schmitt-sody M43 conducted his study in murine. In that study he concluded that 
P-selectin, an adhesion molecule produced by platelets and ECs, play a vital role 
for the interaction of platelets, leukocytes, and ECs in the inflamed joints.  
The results of our study indicate the presence of biomarkers RF, CRP and 
increased platelet count had influence on  a reduced HRV and sympathovagal  
imbalance  in the form of parasympathetic withdrawal and sympathetic over 
activity  in the rheumatoid arthritis patients.  
We assessed the association between biochemical markers RF, C-reactive protein 
and platelet count with autonomic balance in cardiovascular system. We did not 
correlate the clinical parameters like DAS28 (Disease Activity Score 28), fatigue, 
joint involvement, joint tenderness with HRV parameters. 
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In future, increasing number the number of patient recruitment and continuation 
of the study may provide more insight into the significance of biochemical 
markers like RF, CRP & Platelet count etc. 
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CONCLUSION 
The sympathetic activity was increased in the rheumatoid arthritis patients as 
measured by the increased resting heart rate and increased Systolic Blood 
Pressure. The resting HRV in RA subjects indicates that there is a definite 
sympathovagal imbalance in patients with RA in the form of sympathetic over-
activity and parasympathetic withdrawal. The significant decrease in RR interval,   
SDNN and RMSSD parameters indicate parasympathetic withdrawal in the study 
group. Increased LF power and decreased HF power in study group indicate the 
increased sympathetic activity with parasympathetic withdrawal. Increased 
LF/HF ratio also denotes impaired sympathovagal balance with predominant 
sympathetic activity.  
The serum RF and CRP positive RA patients had reduced HRV when compared 
with that of sero-negative RA patients. Elevated platelet count observed in RA 
patients, showed a positive correlation with autonomic imbalance. 
These results showed  that the positive  RF, positive CRP and the increased 
platelet count may play a significant role in  the pathogenesis of  cardiovascular 
complication in RA patients. 
Hence, periodical evaluation of these biomarkersand assessment of 
cardiovascular status by HRV analysis may helpin theearly diagnosis of 
cardiovascular complicationin RA patients. 
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SUMMARY 
The aim of the study was to assess the cardiovascular autonomic functional status   
in the newly diagnosed rheumatoid arthritis (RA) individuals by using resting 
Heart Rate Variabiliy (HRV) analysis. Along with this we assessed the 
association of rheumatoid factor (RF), C - reactive protein (CRP) and platelet 
count with cardiovascular autonomic function. 
 The age and   gender matched 40 study subjects   and 40 healthy controls were 
recruited.  The short term Heart Rate Variability in supine position was taken. 
Serum RF, CRP, and platelet count were evaluated. 
We observed reduced HRV in RA patients, which denotes altered cardiovascular 
autonomic function. We also observed that the positiveRF, CRP andincreased 
platelet count were associated with sympathovagal imbalance. This signifies the 
association of these factors in the pathogenesis of cardiovascular risk in RA 
patients.  
As the resting HRV analysis is a simple, noninvasive tool, it can be included in 
the routine basic investigation of RA subjects.  The periodic assessment of   RF, 
CRP and   platelet count may help in the early diagnosis of cardiovascular 
complication in RA patients. 
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PROFORMA 
 
 1. S.no. :                                                                                          Date: 
 
2. I.D  : 
 
3. Name  :                                                   Address&contact No: 
                                                    
4. Age  : 
 
5. Sex  : 
 
6. Religion :  Hindu / Muslim / Christian / Others (specify) 
 
7. RA –OPD  no. :  
 
8.Occupation  : None / Housewife / labour /Clinical /Professional /Others 
 
9.Per Capita Income : 
                     Number of  family members : 
                     Net family income : 
 
10.Educational Qualification :No education /Class I-V/VI-XII/College/ 
                                              Professional 
 
11.Family history: 
 
12.Duration of illness : 
 
13.Social habits: H/o Alcohol/ Smoking/ Betal nut chewing/Others 
 
14.Past  history: 
 
15.Treatment history:             : 
 
16.Associated comorbidities: 
 
17.Clinical details: 
 
 
 
 
 
 
Joint pain       Duration 
On Examination 
Ht:        Wt: 
Built & Nourishment: 
Respiratory rate:   Pulse:   BP: 
Clinical Examination: 
CVS: 
RS: 
CNS: 
Investigations: 
 Blood: 
  Hb gm% 
  Sugar mg/dl 
  Platelet Count lakh/cu mm 
 Serology: 
  Rheumatoid factor 
  C-reactive protein 
 Others: 
 
 
. 
 
 
 
 
 
 
CONSENT FORM 
IMr/Ms ________________________________ understand that Dr.xxxxxxxxxxxxx 
a postgraduate student in Stanley Medical College and Hospital, Chennai is doing 
the study on Rheumatoid arthritis subjects and control group. I have been made 
to understand that these tests will assess the functioning of my heart. These tests 
are simple, involve taking ECGs, and blood pressure. They donot involve injections 
or taking any medicines and are risk free.I have been familiarized with the testing 
procedures. I am participating in this study willingly. I have not been forced to do 
so.I have also been told clearly that I could withdraw from this study without any 
prejudice. 
Date:          Signature 
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AUTOMATED CELL COUNTER 
 
STUDY GROUP 
S.
N
O
. 
A
G
E 
(y
rs
) 
SE
X 
BM
I 
BL
O
O
D
 
SU
G
A
R 
m
g/
dl
 
SB
P 
m
m
H
g 
D
BP
 
m
m
H
g 
M
EA
N
 
H
R(
bp
m
) 
M
EA
N
 
RR
(m
s)
 
SD
N
N
  
(m
s)
 
RM
SS
D
N
 
(m
s)
 
N
N
 5
0 
LF
 m
s2
 
H
F 
m
s2
 
TO
TA
L 
PO
W
ER
 
LF
 n
u 
H
F 
nu
 
LF
 /
 H
F 
RF
 
CR
P 
Pl
at
el
et
 
co
un
t 
(L
/c
um
m
) 
P1 55 F 25.7 112 112 70 71 851 19.41 22.1 9 352 232 3075 78.3 23.2 1.5 neg pos 2.8 
P2 43 F 22.7 98 122 70 74 816 29.86 26.02 13 308 27.3 2822 72.2 27.8 11 pos pos 3.2 
P3 40 F 21.8 108 112 68 69 873 24.85 27.9 21 612 286 1242 69.4 28.6 2.1 neg neg 3.2 
P4 35 F 30.8 122 134 68 77 784 21.25 18.32 1 547 206 1945 79.4 20.6 2.6 pos neg 3 
P5 45 M 26.0 124 120 70 85 707 17.14 13.13 0 128 253 474 75.3 25.3 0.5 pos pos 3.6 
P6 53 F 26.0 118 116 72 96 626 9.67 5.9 0 15 112 27 88.8 11.2 0.1 pos neg 3.7 
P7 29 M 23.7 92 124 74 78 769 26.27 15.39 3 358 223 1889 78.5 22.3 1.6 pos pos 3 
P8 30 M 24.8 98 130 70 76 792 40.13 18.58 5 301 148 1768 85.2 14.8 2 pos neg 3.1 
P9 55 F 22.6 124 126 72 88 678 22.66 11.84 0 372 240 256 76.4 24 1.6 pos pos 3.4 
P10 53 M 22.0 122 140 72 82 732 18.39 9.8 0 267 195 764 80.5 19.5 1.4 pos pos 3 
P11 53 F 23.7 110 118 70 81 104 41.13 56.73 141 950 274 10765 72.6 27.4 3.5 neg neg 2.6 
P12 52 F 24.0 100 124 74 80 107 36.39 52.29 119 930 233 10532 75 23.3 4 neg pos 3 
P13 35 F 24.8 98 106 70 75 797 28.53 18.1 0 1269 220 2463 78 22 5.8 pos pos 3.7 
P14 35 F 28.4 114 116 70 73 825 26.4 17.8 2 401 214 3444 78.6 21.4 0.2 pos pos 3 
P15 50 F 24.3 126 118 76 69 867 28.99 29.1 37 477 256 5188 73.3 25.6 1.9 pos pos 3.2 
P16 45 M 22.9 108 100 80 78 898 33.14 34.09 55 229 39.6 4392 60.4 39.6 5.8 neg pos 3.1 
P17 45 F 20.0 96 112 74 72 829 14.85 17.65 2 350 98 3481 79 21 3.6 pos pos 3.5 
P18 45 F 27.1 98 110 72 90 666 15.34 5.03 0 286 192 71 80.4 19.2 1.5 pos pos 3 
P19 42 M 25.4 113 118 80 89 671 11.52 5.58 0 304 201 103 79.1 20.1 1.5 pos pos 3.2 
P20 32 F 27.1 93 100 70 93 647 24.92 27.47 32 213 67.7 155 32.3 67.7 0.3 neg neg 3.5 
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P21 42 F 23.8 102 108 80 93 643 27.32 24.6 24 189 67.5 144 51.1 40.8 2.8 pos neg 3.8 
P22 46 M 22.6 118 112 78 79 840 25.96 19.8 3 128 40.6 890 59.4 40.6 3.1 pos neg 3.5 
P23 44 F 22.8 125 114 82 81 805 25.81 17.3 3 598 301 928 69.9 30.1 2 pos pos 2.8 
P24 47 F 23.4 117 116 74 71 843 16.78 13.8 0 674 228 3796 78 22 3 neg neg 2.5 
P25 36 F 20.6 98 120 72 71 844 27.88 21.36 6 568 233 4327 76.7 23.3 2.4 pos neg 3.5 
P26 37 F 31.6 100 108 72 75 795 25.67 17.5 6 278 348 1654 76 24 0.8 pos pos 3.6 
P27 39 F 26.9 102 110 70 73 825 18.24 12.9 2 920 203 1669 79.5 20.5 4.5 pos neg 3.8 
P28 38 M 22.6 104 112 74 72 831 15.51 12.28 0 2165 217 3497 78.3 21.7 10 pos neg 3.7 
P29 30 M 23.2 96 122 70 71 847 41.8 41.27 30 1236 367 2475 66.7 36.7 3.4 pos neg 3.6 
P30 28 F 26.2 96 106 68 71 849 34.14 36.78 43 564 262 2321 73.8 26.2 2.2 pos pos 3 
P31 37 F 21.0 117 116 72 73 821 37.71 36.65 63 932 218 8563 79.5 21.8 4.3 pos pos 2.6 
P32 38 M 22.9 102 112 74 71 842 33.64 36.75 62 1130 275 2656 71.3 27.5 4.1 pos pos 2.8 
P33 35 F 23.6 98 120 70 89 674 24.26 21.14 12 645 662 1289 33.6 66.2 1 pos pos 2.7 
P34 42 M 18.1 106 112 70 85 710 31.98 31.82 48 534 515 435 48.5 51.5 1 pos pos 1.8 
P35 48 M 22.6 102 122 80 92 652 23.5 26.8 38 438 242 203 35 60.7 1.8 pos neg 3.4 
P36 29 F 24.7 90 112 72 80 749 14.97 18.42 1 990 721 1092 20.3 74.8 1.4 neg pos 2.9 
P37 35 M 23.3 117 120 70 84 710 24.6 32.4 46 960 740 832 20.5 74 1.3 pos neg 3.3 
P38 42 F 26.8 97 102 70 82 729 38.43 48.79 164 673 251 2067 68.4 25.2 2.7 pos pos 2.5 
P39 46 F 29.3 100 118 70 83 602 8.89 6.67 0 1246 221 3089 67.0 22.2 5.6 pos pos 2.1 
P40 52 F 27.3 96 120 74 90 593 11.17 7.34 1 2592 1176 2989 73 17.5 2.2 pos pos 3.9 
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C1 35 F 26.7 100 120 70 64 931 65.48 73.29 341 262 313 760 47.5 52.7 0.83 neg neg 2.6 
C2 39 M 22.4 112 122 70 77 778 20.92 13.84 0 26 15 91 64.4 35.6 1.73 neg neg 3.3 
C3 26 F 23.2 108 110 68 68 777 45.14 49.26 140 456 260 6534 67.6 32.4 1.75 neg neg 3 
C4 33 F 32.4 98 100 60 67 885 51.06 56.6 158 668 380 5696 65 35 1.75 neg neg 2.4 
C5 38 M 26.6 100 120 72 81 741 20.89 19.2 4 103 56 831 67.4 32.6 1.83 neg neg 2.3 
C6 27 F 29.9 102 100 60 90 596 15.01 15.03 1 10 16 55 46.2 53.8 0.62 neg neg 1.9 
C7 49 F 24.0 97 110 68 73 819 36.63 38.06 72 326 169 2569 69.7 30.3 1.92 neg neg 2.5 
C8 42 F 27.4 1.4 110 70 70 715 35.62 19.12 69 316 172 2601 68.1 33.2 1.83 neg neg 3.1 
C9 28 M 21.5 100 100 80 68 885 51.06 56.65 158 317 261 2626 55.8 44.2 1.21 neg neg 2.8 
C10 47 F 22.3 96 10 80 64 937 67.17 75.72 170 251 206 1686 56.9 43.1 1.21 neg neg 2.3 
C11 36 F 27.6 98 110 68 68 885 51.06 56.06 158 668 380 5696 65 35 1.75 neg neg 1.1 
C12 44 F 22.6 98 128 68 71 842 63.02 56.38 135 934 415 6111 71.1 28.9 2.25 neg neg 3.5 
C13 52 M 26.4 89 128 80 69 870 77.93 55.13 105 985 508 8345 71.3 28.7 1.93 neg neg 2.6 
C14 53 F 24.8 93 124 84 90 631 19.76 10.63 0 30 13 87 30 13 2.3 neg neg 3.6 
C15 36 F 27.8 88 114 76 80 746 27.78 30.84 43 180 118 1298 63.6 37 1.52 neg neg 1 
C16 45 F 21.6 98 112 86 75 805 21.08 19.02 6 146 84 2490 67.8 30.5 1.73 neg neg 2.3 
C17 48 M 19.2 100 120 80 68 881 38.42 30.11 28 328 195 4680 73.2 26.8 1.68 neg neg 4.5 
C18 53 F 24.2 89 120 70 67 891 147.2 198 45 195 298 845 49.5 51.2 0.65 neg neg 2.5 
C19 52 F 28.1 96 120 70 63 927 46.92 48.4 86 272 341 784 40.1 58.2 0.79 neg neg 4.3 
C20 35 M 24.5 118 100 60 62 910 38.78 48.7 5 170 211 1389 50.8 49.2 0.8 neg neg 2.2 
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C21 29 F 22.9 93 120 72 64 802 84.12 73.2 68 212 320 985 46.8 53.7 0.66 neg neg 2.3 
C22 39 F 19.7 118 110 70 65 896 24.76 22.7 17 98 212 1712 56 44 0.46 neg neg 2.6 
C23 37 M 24.3 102 118 74 80 754.3 47.3 53.8 63 548 1321 5234 35.2 67.5 0.41 neg neg 2.8 
C24 38 F 19.6 100 120 74 72 830 41.2 43.9 88 976 962 2018 52.4 50.1 1.01 neg neg 1.9 
C25 43 M 17.9 87 100 70 65 860 70.32 70.43 143 452 521 1097 45.3 44.7 0.83 neg neg 3 
C26 52 M 30.8 103 108 70 68 873 24.66 34.31 40 118 564 678 17.2 73.1 0.02 neg neg 2.7 
C27 29 F 24.2 96 104 64 74 797 49.88 64.36 205 843 1356 3245 37.6 62.2 0.62 neg neg 2.3 
C28 46 M 22.3 110 114 70 69 865 70.23 75.24 174 2088 1687 5342 62.3 35.2 1.23 neg neg 1.9 
C29 44 F 23.5 84 118 76 66 921 52.13 58.32 142 936 834 4237 59.8 40.1 1.12 neg neg 2.5 
C30 47 F 27.6 98 110 70 83 723 35.4 34.9 54 367 545 1954 44.4 55.7 0.67 neg neg 2.9 
C31 55 F 24.8 97 112 72 62 976 64.12 76.87 173 959 2035 3897 35.6 65.3 0.47 neg neg 1.8 
C32 37 F 22.3 100 108 70 65 943 80.23 100.3 202 1102 2564 5598 53.7 48.1 0.42 neg neg 3 
C33 44 F 25.5 96 108 70 69 861 33.24 36.73 67 357 586 1670 45.3 52.3 0.6 neg neg 2.6 
C34 45 F 20.2 102 110 68 86 696 47.3 57.52 123 513 1324 2023 27.4 72.3 0.38 neg neg 3.2 
C35 42 M 21.8 97 126 80 76 784 35.8 40.91 118 241 727 1038 27.2 71.9 0.33 neg neg 2.4 
C36 32 F 25.0 93 110 72 70 831 72.2 70.12 159 879 1842 3531 52.9 46.1 0.48 neg neg 2.6 
C37 43 F 26.5 102 130 80 63 945 84.15 105.3 192 608 2543 5758 52.5 41.7 0.23 neg neg 2.3 
C38 37 F 24.9 87 120 70 65 922 53.81 55.81 139 476 853 2217 58.6 41.0 0.55 neg neg 1.4 
C39 35 F 26.7 107 110 68 73 823 69.68 90.17 180 689 789 1578 45.7 56.3 0.87 neg neg 3 
C40 50 F 25.6 126 130 68 63 964 84.15 94.35 203 753 2364 5785 53.5 48.0 0.31 neg neg 2.5 
 
